Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Queensland Health
Federal Trade Commission
US Army
UBS
McKinsey
Cerilliant
Chinese Patent Office
Merck

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 088528

« Back to Dashboard

NDA 088528 describes HYDROFLUMETHIAZIDE, which is a drug marketed by Par Pharm, Watson Labs, and Usl Pharma, and is included in six NDAs. Additional details are available on the HYDROFLUMETHIAZIDE profile page.

The generic ingredient in HYDROFLUMETHIAZIDE is hydroflumethiazide; reserpine. There are two drug master file entries for this compound. Additional details are available on the hydroflumethiazide; reserpine profile page.
Summary for 088528
Tradename:HYDROFLUMETHIAZIDE
Applicant:Watson Labs
Ingredient:hydroflumethiazide
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 088528

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength50MG
Approval Date:Aug 15, 1984TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
McKinsey
UBS
Dow
US Army
Moodys
Federal Trade Commission
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.